Receptor for advanced glycation endproducts (RAGE) modulates glyoxalase-1 enzyme activity in mouse models.

by

Smruti S. Gore

Submitted to the graduate degree program in the department of pharmacology and toxicology and the graduate faculty of the University of Kansas in partial fulfillment of the requirements for the degree of **Master of Science**.

____

Dr. Shirley ShiDu Yan, Ph.D., Co-chair

____

Dr. Nancy Muma, Ph.D., Co-chair

____

Dr. Jai Subramanian, Ph.D.

Date defended: May 24th, 2019

The thesis committee for Smruti S. Gore certifies that this is the approved version of the following thesis:

Receptor for advanced glycation endproducts (RAGE) modulates glyoxalase-1 enzyme activity in mouse models.

Dr. Shirley ShiDu Yan, Ph.D., Co-chair

Dr. Nancy Muma, Ph.D., Co-chair

Date approved: September 6th, 2019

ABSTRACT

Alzheimer's disease (AD) is the most common cause of dementia in the world. AD is characterized pathologically by the presence of Amyloid-β (Aβ) plaques and tau neurofibrillary tangles (NFTs). Advanced glycation endproducts (AGEs), which are derived from alpha-dicarbonyls such as methylglyoxal (MG), form endogenously with physiological aging. These AGEs have been observed to co-localize with both the plaques and NFTs in AD patients' brains.

Receptor for advanced glycation endproducts (RAGE) has been implicated in the pathogenesis of AD. However, the exact mechanism by which RAGE contributes to AD pathology is only partially known. Glyoxalase-1(GLO1) is an important enzyme involved in the detoxification of precursors of AGEs, which serve as the highly reactive primary ligands for RAGE. GLO1 is found to be downregulated in the brains of advanced stage AD patients whereas RAGE is overexpressed in such brains.

Aging is associated with increased generation and deposition of AGEs, resulting from non-enzymatic glycation (or oxidation) of proteins and lipids. Higher AGE formation is associated with a multitude of cellular and synaptic disturbances. Thus, to see the direct effect of age on enzyme activity, we first performed a study of wild type (WT) animals from 3 to 30 months and found that beyond 12 months of age, GLO1 activity significantly decreases. This shows that aging can be a major factor contributing to AD pathology through the downregulation of GLO1 activity. For uniformity, we used 12 months old mice for all further studies.

In order to investigate whether RAGE directly modulates GLO1 enzyme activity and protein expression, we used previously generated multiple transgenic (Tg) non-AD mouse models by either genetic deletion of RAGE (RAGE knockout) or the introduction of signal deficient

dominant-negative mutant RAGE (DNRAGE). They were, in the past, characterized for RAGE and subsequent RAGE-mediated signal transduction in our lab. GLO1 enzyme activity was measured spectrophotometrically while GLO1 protein expression was determined with western blotting.

The Tg mice displayed either a) an increase in GLO1 enzyme activity, and/or b) an increase in GLO1 protein expression when compared with age-matched WT controls. Global RAGE knockout (RO) and neuronal RAGE knockout (nRKO) mice showed significantly higher GLO1 enzyme activity compared to WT controls. RO mice showed a significant increase in the protein expression but nRKO mice did not. Similarly, the mice with DNRAGE targeted to cortical neurons (neuronal DNRAGE) and to microglia (DNMSR) exhibited an increase in GLO1 enzyme activity compared with WT mice but showed no significant change in protein expression. This differential effect in protein expression can be due to the difference in post-translational modification such as disulfide bridge formation or presence of GLO1 variations. It could also be the effect of normal or higher GLO1 activity in non-neuronal or microglial cells.

Given the clear modulation of GLO1 by RAGE variation, we performed the GLO1 enzyme activity and expression assays in Tg mice modeling amyloid plaque development by expressing a mutant form of human APP leading to overproduction of Aβ (mAPP) to see if similar effects are observed in a mouse model showing AD-like pathology. We also crossed these mAPP mice with RO mice to develop RAGE-deficient mAPP mice (mAPP/RO). The mAPP mice showed a significant reduction in both GLO1 enzyme activity and protein expression. mAPP/RO mice and RO mice showed higher GLO1 activity and protein expression compared to mAPP mice. These findings highlight that RAGE-dependent signaling downregulates GLO1 enzyme activity and the

deletion of RAGE protects against this decrease. Also, it supports the hypothesis that loss of RAGE-mediated signaling leads to an increase in GLO1 activity, whereas specific APP mutation (and Aβ overproduction) contributes to the decrease in GLO1 activity.

Taken together, these data show that RAGE functions as an active modulator of GLO1 enzyme activity, thereby providing new insights into a mechanism by which the RAGE-dependent signaling cascade contributes to the pathogenesis of AD. Thus, RAGE deletion or blockade of RAGE signaling may be a potential target for developing treatments for preventing the progression of AD and related degenerative disorders through modulation of GLO1 function.

ACKNOWLEDGEMENTS

First, I would like to thank my advisor**, Dr. Shirley ShiDu Yan** for always guiding and encouraging me throughout this project. Her constant support helped me endure through all the problems we faced during the project. I am honored to have been part of her research lab and to have worked with her.

I would also like to extend my thanks to **Dr. Shi Fang Yan** for her immense patience in teaching me the required techniques and making sure that I was making necessary progress.

I would like to thank my committee members, **Dr. Nancy Muma** and **Dr. Jai Subramanian**, for being understanding and supportive and for pushing me to work hard. I will always be grateful for their encouraging words and the trust they expressed in me.

Next, I would like to thank my lab members and peers: **Dr. Erika Nolte**, for all the little pieces of advice I received from her over the last two years about topics ranging from seminar presentations to interviewing, **Shreya Indulkar** for always being there for me and **Dr. Asma Akhter** for making the two years of lab work more enjoyable.

Finally, I express immense gratitude to **my parents**, **my family** and to **my friends** for providing me with unfailing support and continuous encouragement throughout last two years of study and through the process of researching and writing this thesis. This accomplishment would not have been possible without them. Thank you all.

TABLE OF CONTENTS

ABSTRACT iii

ACKNOWLEDGEMENTS vi

INTRODUCTION 1

ALZHEIMER'S DISEASE 1

ADVANCED GLYCATION ENDPRODUCTS (AGEs) 1

RAGE 3

RAGE and microglia 4

RAGE and neuronal function 4

GLYOXALASE-1 (GLO1) 6

MATERIALS & METHODS 8

ANIMALS 8

Generation and characterization of global knockout of RAGE mice 8

Generation and characterization of conditional neuronal knockout of RAGE mice 8

Generation and characterization of transgenic mice with cytosolic dominant-negative RAGE (neuronal DNRAGE) 10

Generation of transgenic mice with Dominant-negative effect targeted to microglia (DNMSR-microglial DNRAGE) 10

Generation of transgenic mAPP AND mAPP/RO mice [28] 11

Animal models 12

GLO1 ENZYME ACTIVITY KINETIC ASSAY 13

Calculation of enzyme units 13

WESTERN BLOT 14

Antibodies 16

STATISTICAL ANALYSES 17

RESULTS 18

1) Effects of physiological aging on GLO1 activity and protein expression in 3 to 30-month-old WT mice ... 18

2) Effects of global RAGE knockout on GLO1 activity and protein expression in 6- and 12-months old mice ... 18

3) Effects of neuronal RAGE knockout on GLO1 activity and protein expression in 12-month old mice ... 19

4) Effects of neuronal DNRAGE mutant on GLO1 activity and protein expression in 12-month old mice ... 19

5) Effects of microglial DNMSR mutant on GLO1 activity and protein expression in 12 months old mice ... 20

6) Effects of mutant APP overexpression on GLO1 activity and protein expression in 12 months old mice ... 21

DISCUSSION ... 37

GLO1 enzyme activity is dependent on RAGE and is modulated in age-dependent manner. . 38

RAGE is required both in neurons and microglia for regulating GLO1 activity. ... 39

GLO1 protein levels are not altered in mice with cell-type specific RAGE mutations. ... 41

APP mutation regulates GLO1 activity and protein level through RAGE signaling. ... 43

REFERENCES ... 49

LIST OF ABBREVIATIONS

AD- Alzheimer's disease
Aβ- Amyloid β protein
NFTs- Neurofibrillary tangles
AGEs- Advanced glycation endproducts
MG- Methylglyoxal
GSH- Glutathione
RAGE- Receptor for advanced glycation endproducts
GLO1- Glyoxalase-1 enzyme
WT- Wild type
mAPP- mutant amyloid precursor protein
RO- RAGE knockout
nRKO- neuronal RAGE knockout
DNRAGE- Dominant-negative form of RAGE lacking RAGE signaling targeted to neurons
DNMSR- Dominant-negative form of RAGE lacking RAGE signaling targeted to microglia
TBS- Tris buffer saline solution
TBST –Tris buffer saline solution with tween 20
BSA- Bovine serum albumin
Tg- Transgenic
CK2-CAMKIIA- Calcium-calmodulin-dependent kinase II
PDGF- Platelet-derived growth factor
PCR- Polymerase chain reaction
MSR- Macrophage scavenger receptor
MAPK-Mitogen-activated protein kinase

LIST OF TABLES

Table 1: Details of animal models used for experiments 12
Table 2: Summary of antibodies used 16
Table 3: Summary of GLO1 activity and expression in various mouse models compared to WT 22

LIST OF FIGURES

Figure 1: Effect of age on GLO1 enzyme activity in 3 to 30 months old WT mice. 24
Figure 2: Effect of global RAGE knockout on GLO1 enzyme activity and protein expression in 6 months old WT and RO mice. 26
Figure 3: Effect of global RAGE knockout on GLO1 enzyme activity and protein expression in 12 months old WT and RO mice. 28
Figure 4: Effect of neuronal RAGE knockout on GLO1 enzyme activity and protein expression in 12 months old WT and nRKO mice. 30
Figure 5: Effect of neuronal DNRAGE on GLO1 enzyme activity and protein expression in 12 months old WT and neuronal DNRAGE mice. 32
Figure 6: Effect of DNMSR mutant on GLO1 enzyme activity and protein expression in 12 months old WT and DNMSR mice. 34
Figure 7: Effect of presence of mutant APP on GLO1 enzyme activity and protein expression in 12 months old WT, APP, APP/RO and RO mice. 36

INTRODUCTION

ALZHEIMER'S DISEASE

Alzheimer's disease (AD) is a progressive, and irreversible neurodegenerative disorder. It is characterized by memory loss, personality changes, and cognitive impairment and affects 1 in 10 people of ages 65 or older, making it the most common form of dementia in older adults [1-6]. It is predicted to affect approximately 42 million people worldwide by the year 2020[7]. The main pathological features of AD are the formation of amyloid-β (Aβ) deposits in the anterior cerebral cortex and hippocampus as well as the formation of intracellular neurofibrillary tangles (NFTs) resulting in neuronal cell death [3, 5, 8-11]. Aβ, which is a 40–42 amino-acid peptide generated by proteolytic cleavage of the amyloid precursor protein (APP), and NFTs, which are composed of a hyper-phosphorylated microtubule-associated tau(τ) protein, are the major markers of progression of AD [3, 5, 6, 11-22].

ADVANCED GLYCATION ENDPRODUCTS (AGEs)

Advanced glycation endproducts (AGEs) are members of a heterogeneous class of molecules, which modify cellular function by distinct mechanisms including ligation and activation of signal transduction receptors. These AGEs are the products of non-enzymatic glycation (or oxidation) of proteins and lipids. The levels of AGEs increase during biological aging due to decreased efficiency of homeostatic processes. AGEs also further contribute to the normal physiological aging process [22, 23]. When their production is accelerated, they have a causative role in the complications of diabetes mellitus (DM) and several neurodegenerative diseases, including AD,

Parkinson's, and Huntington's diseases [22, 24-27]. Excess AGE accumulation is detrimental to neurons and is believed to be a key to the pathogenesis of cognitive decline in normal aging and specific chronic diseases of aging [28-31].

Long-lived proteins such as Aβ and hyper-phosphorylated tau that accumulate in AD brain are highly susceptible to AGE modification. AGE modified Aβ or tau protein result in increased oxidative stress and chronic inflammation, accelerating AD pathology and neuronal perturbation [32-40]. Moreover, Aβ or tau glycation results in increased aggregation and subsequent formation of senile plaques or NFTs, the major pathological feature of AD suggesting that AGE modification is an important risk factor for AD[24, 41-47]. Although increased accumulation of AGEs in brain, as seen in aging, diabetes, or neurodegenerative diseases, speeds up oxidative damage to neurons contributing to synaptic dysfunction and cognitive decline, the underlying mechanisms for this accumulation are not well understood [48].

These AGEs, formed by non-enzymatic glycation of proteins and lipids on exposure to sugars, play an important role in normal aging and in degenerative diseases such as AD, atherosclerosis and ALS (amyotrophic lateral sclerosis) [24, 47]. Receptor for these AGEs (RAGE) is a multi-ligand, transmembrane receptor expressed by neurons, microglia, astrocytes, cerebral endothelial cells, pericytes, phagocytes, cardiac myocytes, hepatocytes, and smooth muscle cells [49]. Increase in the expression of RAGE is seen in AD-affected brain regions [50-52]. RAGE and its isoforms play an important role in the regulation of metabolism, inflammation, and epithelial survival in stress conditions [14, 53-55].

In addition to AGEs' ability to directly alter the structure and function of targeted proteins within cells that causes cell or tissue damage, emerging evidence has also demonstrated AGEs as a signaling ligand, interacting with RAGE[22, 56-60]. AGEs elicit signal transduction changes that adversely affect numerous peripheral organs. Although AGE accumulation is increased in cortical neurons, hippocampal pyramidal neurons, astrocytes, and other glial cells in aging and AD brain[14, 45, 56, 59, 61, 62], the direct effect of AGEs–RAGE interaction on brain function, and on alteration in enzyme function and levels, still remains largely unknown.

RAGE

RAGE was first identified as a cell surface receptor of the immunoglobulin superfamily for AGEs [5, 63-68]. There are three major isoforms of RAGE. These different RAGE isoforms are generated as the result of alternative splicing and are defined as being the full-length RAGE, dominant negative RAGE (DNRAGE), and secretory RAGE (sRAGE) [53, 54, 68]. Increased expression of RAGE occurs in neuronal and non-neuronal cells in the peripheral and central nervous system in aging, diabetes, and AD affected individuals, where RAGE ligands are upregulated [43, 51, 64, 69-73].

RAGE and microglia

RAGE-dependent signaling in microglia contributes to neuroinflammation especially in mouse models of AD that ultimately impairs neuronal function and directly affects amyloid accumulation [74, 75]. Deposition of cross-linked insoluble protein aggregates such as amyloid plaques is characteristic for Alzheimer's disease. Microglial activation by these extracellular deposits has been proposed to play a crucial role in functional degeneration as well as neuronal cell death[76]. AGEs activate specific signal transduction pathways, resulting in the up-regulation of various proinflammatory signals such as cytokines [interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-a)] and nitric oxide synthase (NOS)[77] . The blockade of microglial RAGE (by using Cre/loxP technology) is found to have beneficial effect on Aβ-mediated neuronal changes relevant to AD pathogenesis [3, 10, 63, 64, 73, 74, 78-80].

RAGE and neuronal function

Genetic deficiency of neuronal RAGE protects against AGE-induced synaptic injury. RAGE and nuclear factor kappa B (NF-κB) have been related to neuronal death [81]. Interaction of Aβ with neuronal RAGE leads to NF-κB activation, indicating a possible role of neuronal RAGE in inflammation[72]. Aβ induces a RAGE-dependent pathway that involves activation of p38 MAPK, resulting in Aβ internalization and leads to mitochondrial dysfunction in cortical neurons[82]. RAGE blockade can be a target for development of interventions aimed at preventing progression of cognitive decline in aging and AGE-related neurodegenerative disorders[3, 5, 20, 27, 28, 48, 66, 82-85].

METHYLGLYOXAL

Methylglyoxal (MG) is a highly reactive dicarbonyl compound formed in vivo as a major byproduct of glycolysis. MG is an endogenous byproduct of the normal metabolism of carbohydrates along with lipids, and proteins, inevitably produced spontaneously or enzymatically [86, 87].

During glycolysis, MG is readily formed under alkaline conditions from glyceraldehyde or dihydroxyacetone[88]. Intermediate metabolites such as acetoacetate from lipids, and succinyl acetone and amino acetone from threonine and glycine metabolism, are also endogenous sources of MG . Accumulation of MG is highly toxic, since it readily reacts in vivo with basic phospholipids and nucleotides, and with lysine and arginine residues of proteins, leading to AGE formation [89-92]. MG can also impair the antioxidant system by depleting glutathione (GSH) levels[87]. It has been considered as a possible causative agent in a number of pathologies, such as diabetes [93, 94], hyperalgesia and inflammation, aging disorders[5, 59], Alzheimer's disease[95, 96], epilepsy, autism[97], and anxiety[98, 99] among others.

MG concentration in human plasma is in the range of 0.1–0.6 µM, and about 10- to 20 fold higher in the cerebrospinal fluid [100-102]. These elevated levels of MG can make nerve cells more susceptible to AGE formation, which is thought to be a relevant factor in the development of neurodegenerative diseases[103]. MG can induce irreversible loss of protein function, including cross-linking, as well as contributing to oxidative stress[104]. MG is the major precursor in the

formation of AGEs. Under normal physiological conditions, MG is detoxified by the glyoxalase system to give D-lactate, with GLO1 as the key rate-limiting enzyme in the process [86].

GLYOXALASE-1 (GLO1)

AGE precursor compounds are cellularly detoxified by the glyoxalase system, consisting of GLO1 and 2. GLO1 is a cytosolic enzyme which catalyzes the isomerization of hemithioacetal adducts, formed in a spontaneous reaction between a glutathionyl group (such as GSH) and aldehydes (such as MG). Since alpha-oxoaldehydes, such as MG are important intracellular AGE precursors [105], GLO1 has an important role in reducing cellular AGE levels. Binding of AGEs to RAGE causes suppression of GSH thus increasing the intracellular oxidative stress[60, 106]. Decrease in GSH leads to decreased GLO1 activity [107]. Also, decrease in GLO1 activity due to aging and oxidative stress results in increased glycation and tissue damage. In vitro studies with endothelial cell lines have shown that GLO1 over-expression prevents intracellular AGE formation [108]. GLO1 levels are diminished in brains of older adults and in AD patients' brains. However, the mechanism behind the change is still unknown. Understanding this mechanism of modulation will help in precise targeting of GLO1 for treatment of AD. [23, 46, 86, 90, 91, 93, 94, 98-100, 107-145]

As high levels of AGEs are involved in GLO1 downregulation, we hypothesized that RAGE decreases GLO1 activity in transgenic non-AD (RAGE knockout and DNRAGE) and AD (mAPP) mouse models. To test the proposed hypothesis, we divided the experiments in three parts to check:

1. effect of physiological aging 2. effect of RAGE deletion or signaling blockade and 3. effect of mutant APP on GLO1 enzyme activity and protein expression.

As RAGE is expressed in neurons and non-neuronal cells (i.e., glial, endothelial cells, and pericytes of the blood–brain barrier) [48], the results obtained from global RAGE knockout(RO) mice do not explain which cell types are important in AGE-induced impairments. Therefore, study of transgenic mice with neuronal RAGE knockout (nRKO) and DNRAGE mutant specifically in the microglia and neurons was done[28, 48, 146], to address the question of whether the activities of neuronal and microglial RAGE are responsible for AGE-induced GLO1 reduction [48].

The purpose of this thesis is to investigate the link between GLO1 activity and protein levels and presence of RAGE and provide a better understanding of their role in Alzheimer's disease pathophysiology.

MATERIALS & METHODS

ANIMALS

Generation and characterization of global knockout of RAGE mice

For our experiments, transgenic (Tg) RO mice generated previously were used. Homozygous RAGE null mice (generated in the 129 strain) were backcrossed three generations into C57BL/6; mating of heterozygous RAGE null males and females yielded heterozygous mice, as well as wild-type RAGE-bearing (RAGE$^{+/+}$) and homozygous RAGE null animals (RAGE$^{-/-}$). RAGE null mice are viable and display normal reproductive fitness [66]. In all cases, age-matched littermates (WT-wild type) were employed as controls. The mice were characterized for RAGE and signaling markers in our lab. The institutional Animal Care and Use Committee of the University of Kansas approved all protocols.

Generation and characterization of conditional neuronal knockout of RAGE mice

Previously generated nRKO mice were used for experiments. Our lab developed a model system in which neuronal expression of RAGE, in particular in the brain region responsible for learning and memory, is deleted so that consequences of receptor–ligand interaction could be assessed [48]. To this end, Cre recombinase neuronal RAGE null mice, termed as Tg nRKO mice were created by crossing neuronal-targeted and region-restricted Tg mice that express Cre recombinase in the entire forebrain, under the control of the forebrain-specific calcium-calmodulin-dependent kinase II (CAMKIIA, CK2) promoter to generate deletion of neuronal RAGE in the entire hippocampus and cortex. Cre-loxP system was used to generate the targeting vector and the RAGE/flox mice (performed by Ozgen Inc., Bentley DC, WA, and Australia).

The targeting vector consists of three fragments: the 5′ homology arm, the 3′ homology arm, and loxP arm. Two loxP sites flanking RAGE exons 2–4 allow for Cre-mediated deletion using Cre recombinase. Excision of exons 2–4 by Cre recombinase results in a frame shift and early stop codon from the mouse RAGE sequence, which block RAGE expression. Our lab first made homozygous RAGE floxed allele mice (*RAGE* $^{flox/flox}$); then *RAGE*$^{flox/flox}$mice were crossed with neuronal target CK2 mice to generate homozygous floxed and hemizygous Cre nRKO mice (*RAGE*$^{flox/flox}$*/CK2-Cre*), which were then verified by analysis of tail DNA with PCR amplification using primers for *flox* (700 bp) and *Cre* transgene (300 bp). Immunoblotting of cortical homogenates with anti-RAGE antibody showed significant reduction of RAGE expression levels in cerebral cortex of nRKO mice compared with non-Tg mice (~80% reduction *versus* non-Tg brain, $P<0.01$). The observed incomplete suppression of RAGE expression was due to the use of brain homogenates, which contained non-neuronal cells with intact RAGE. Confocal microscopy with double immunostaining of RAGE and MAP2(neuron specific protein marker) clearly demonstrated that there was virtually no RAGE signal in MAP2-positive neurons in cortex and hippocampus of nRKO mice, thereby verifying RAGE depletion in cortical neurons in the brain of nRKO mice.

Generation and characterization of transgenic mice with cytosolic dominant-negative RAGE (neuronal DNRAGE)

Previously generated neuronal DNRAGE mice were used for the experiments. We used the transgenic mice with signal-transduction-deficient mutants of RAGE in which the cytosolic domain of the receptor was deleted, thereby imparting a dominant-negative (DN)-RAGE effect, targeted to neurons (neuronal DNRAGE) driven by the platelet-derived growth factor-B (PDGF-B) chain promoter [66, 72]. These neuronal DNRAGE mice were characterized, demonstrating localization of DNRAGE in cortical neurons previously in our lab.

Generation of transgenic mice with Dominant-negative effect targeted to microglia (DNMSR-microglial DNRAGE)

Previously generated transgenic mice with signal-transduction-deficient mutants of RAGE in which the cytosolic domain of the receptor has been deleted, thereby imparting a dominant-negative RAGE effect, targeted to microglia (DNMSR) driven by the macrophage scavenger receptor (MSR) type A promoter, were used for this study[20, 75, 80]. Founders were identified by mouse tail biopsy; DNA was prepared, and Southern blot was performed using human RAGE cDNA as a probe and by PCR. Mice were generated and hemizygous mice backcrossed eight generations into C57BL/6 were used in our studies. Human DNRAGE transgene was identified by PCR using primers 4A-5'AGGATCAGGGCTGGGAACTCTA, and

4B-5' TCCCCCTGAACCTGAAACATAAAA.

Generation of transgenic mAPP AND mAPP/RO mice [28]

Previously generated transgenic mice with neuronal overexpression of a mutant human form of APP (Tg mAPP or mAPP, J-20 line, Jackson Lab) driven by the PDGF-B chain promoter were used in this study[28, 147]. These mAPP mice are a well-established mouse model of AD and exhibit many features of AD neuropathology[28, 72], and have been used in previously published studies [72, 73, 78, 147-150]. Homozygous RAGE null mice (RO mice) were backcrossed into C57BL/6 strain for more than 12 generations and were crossed with mAPP mice to generate mAPP/RO mice. Age-matched non-genetically modified WT littermates were used as controls in our studies. Mice were maintained on normal rodent chow and allowed free access to food and water. Genomic DNA was isolated from tail biopsies and subjected to PCR analysis to identify the deficiency of RAGE or human APP gene. The mice were anesthetized with ketamine (100 mg/kg) and Xylazine (10 mg/kg) and flush perfused transcardially with 0.9% saline. Brains were removed and divided sagittally. One hemibrain was post-fixed in phosphate-buffered 4% paraformaldehyde (pH 7.4) at 4°c for 26h and sectioned at 20 mm with a vibratome (Leica); the other hemibrain was dissected to hippocampus and cortex, snap frozen and stored at –80°c for protein analysis.

Animal models

Details of all animal models used are summarized in the following table: Table 1.

Table 1: Details of animal models used for experiments

No.	Genotype	Genetic Manipulation	RAGE (Receptor)	RAGE signaling	AD-like pathology
1	RO	Global RAGE knockout	-	-	-
2	nRKO	Neuronal RAGE knockout	- (in neurons)	-	-
3	Neuronal DNRAGE	Signal deficient mutant targeted to neurons	+	- (in neurons)	-
4	DNMSR	Signal deficient mutant targeted to microglia	+	- (in microglia)	-
5	mAPP	Overexpression of APP	+	+	+
6	mAPP/RO	APP crossed with RO	-	-	-

GLO1 ENZYME ACTIVITY KINETIC ASSAY

GLO1 catalyzes the isomerization of the hemithioacetal formed non-enzymatically from MG and GSH to S-D-lactoylglutathione. In this assay, the activity of GLO1 was measured spectrophotometrically by following the increase in OD240 for which the change in molar extinction coefficient $\Delta\varepsilon240=3.37\ mM^{-1}\cdot cm^{-1}$. The hemithioacetal was pre-formed in situ by incubation of MG and GSH in 50 mM sodium phosphate buffer (0.02 M Sodium phosphate dibasic heptahydrate, 0.03 M Sodium phosphate monobasic monohydrate, pH 6.6) at 37°C for 10 min. The tissue sample homogenate was then added, the OD240 was monitored over 10 min, and the initial rate of increase in OD240 and hence GLO1 activity was deduced with correction for blank. GLO1 activity is given in units per mg of protein where one unit is the amount of enzyme that catalyzes the formation of 1 μmol of S-D-lactoylglutathione per min under assay conditions.

Calculation of enzyme units

GLO1 enzyme activity was determined using the following set of equations:

$$\frac{\text{Units}}{\text{mL}}\text{enzyme} = \frac{\left[\left(\frac{\Delta\text{A240nm}}{\text{min for test}} - \frac{\Delta\text{A240nm}}{\text{min for blank}}\right)(\text{Total volume of assay})(\text{dilution factor})\right]}{[(\text{Extinction Coeff. of S} - \text{Lactoylglutathione})(\text{Volume of enzyme used})]}$$

Where. Total volume (in milliliters) of assay=0.2 (200 ul reaction)

Millimolar extinction coefficient of S-Lactoylglutathione at 240 nm= 3.37

Volume (in milliliter) of enzyme used= 0.0067 (6.7 ul protein samples)

$$\text{Units/ml enzyme} = \frac{(\Delta\text{A240nm/min Test} - \Delta\text{A240nm/min Blank})(0.2)(1)}{(3.37)(0.0067)}$$

$$\text{Units/mg protein} = (\text{units/ml enzyme})/(\text{mg protein/ml enzyme})$$

WESTERN BLOT

Total protein extracts were prepared from the dissected frontal cortical brain from snap-frozen hemi-brains by homogenization with 1× RIPA buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM Na_2EDTA, 1 mM EGTA,1% NP-40, 1% Sodium deoxycholate, 2.5mM sodium pyrophosphate,1 mM Na2VO4, Catalog #9806, Cell Signaling Technology, MA) containing 1× protease inhibitor cocktail (104 mM AEBSF, 80 µM Aprotinin, 4 mM Bestatin, 1.4 mM E-64, 2 mM Leupeptin and 1.5 mM Pepstatin A, Roche applied Science, IN) and 1 mM PMSF (Phenylmethylsulphonyl fluoride) OR with 0.01% Triton-X solution in DPBS (Dulbecco's Phosphate-buffered saline, KCl, KH_2PO_4, NaCl, $Na_2HPO_4.7H_2O$, Catalog #A14190144, Gibco-Thermo Fisher Scientific). Total protein extracts from cells were prepared using 1× cell lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM Na_2EDTA, 1 mM EGTA, 1% Triton, 2.5mM sodium pyrophosphate,1 mM Na2VO4, Catalog #9803, Cell Signaling Technology, MA) containing 1× protease inhibitor cocktail and 1 mM PMSF. Protein concentrations of the tissue or cell lysates were spectrophotometrically determined with Bio-Rad protein assay dye reagent (acidified Coomassie Brilliant Blue G-250) concentrate kit at 595nm. Equal amount of protein from each sample was loaded and then separated by SDS/PAGE (12% Bis–Tris gel, Catalog# NP0301, Invitrogen/Thermo Fisher Scientific, Austin, USA), and then electrophoretically transferred to 0.45 µm nitrocellulose membranes (Catalog# 162-0094, Bio-Rad Laboratories, Hercules, CA, USA) using NuPAGE running buffer (50 mM MES, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.3, 50 ml 10 X buffer in 1 L milliQ H2O, Thermo Fisher Scientific, Cat. No. NP0002, Lot no. 1958831). Non-specific binding was blocked by 5% non-fat milk in TBS buffer (30 ml 5M NaCl and 20 ml 1M Tris-HCl in 1L milliQ H2O, 20 mM Tris–HCl, 150 mM NaCl, pH 7.6) for 1 h at room temperature. The membrane was incubated in diluted primary antibody in BSA

(bovine serum albumin) in TBST (TBS containing 0.1% Tween-20, pH 7.6) overnight with gentle shaking at 4 °C. Primary antibodies used for the reactions were as follows: rabbit anti-GLO1 (1:3000 Catalog #SC-67351, Santacruz biotechnology) and mouse anti-β-actin (1:5000, Catalog #A5316, Sigma, St. Louis, MO, USA). The membrane was washed with TBST and then incubated with the corresponding horseradish peroxidase-conjugated secondary antibody: goat anti-rabbit IgG or goat anti-mouse (1:10 000, Catalog #A6154 or #A4416, Sigma, St. Louis, MO, USA), for 1 h with gentle shaking at room temperature to identify sites of binding of each primary antibody. Finally, the chemiluminescent signal from immunoreactive band was detected with ECL using an enhanced chemiluminescent western blot system (Solution A: Luminol solution, Solution B: Peroxide solution, GE Healthcare, NJ). GLO1 protein expression was quantified as ratio of intensity of GLO1 band to the intensity of β-Actin band (loading control) immunoreactive bands by immunoblotting with anti-GLO1 and anti-β-Actin antibodies. Data from western blot was quantified using ImageJ (NIH) software and significance was analyzed using GraphPad Prism 8.

Antibodies

The antibodies used in the experiments are listed in following table: Table 2.

Table 2: Summary of antibodies used

No.	Antibody	Dilution	Cat. No.	Lot No.	Vendor
1	Rabbit polyclonal anti-glyoxalase-1 antibody	1:3000	Sc-67351	DO114	Santacruz Biotech.
2	Anti-rabbit IgG (whole molecule)–peroxidase antibody produced in goat	1:10000	A6154	SLBV9141	Sigma-Aldrich
3	Monoclonal anti-β-actin antibody produced in mouse	1:5000	A5316	SLBS6528	Sigma-Aldrich
4	Anti-mouse IgG (whole molecule)–peroxidase antibody produced in goat	1:10000	A4416	SLBW491 7	Sigma-Aldrich
5	Rabbit polyclonal anti-RAGE antibody	1:1000	GTX23611	41906	GeneTex

STATISTICAL ANALYSES

All statistical analyses were conducted using GraphPad Prism 8(GraphPad software Inc., La Jolla, CA). Shapiro-Wilk's test for normality and Brown-Forsythe-Levene test for homogeneity of variance were used to determine whether the data met the requirements for a parametric analysis of variance. Two-tailed student's t-test, one-way ANOVA, and two-way ANOVA were used for analyses (as indicated in the figure descriptions) followed by Tukey's or Dunn's test for post-hoc multiple comparisons where required. All results were reported as mean ± S.E.M. $^{*}p<0.05$ was considered significant. Other significant p-values were designated as $^{**}p<0.01$, $^{***}p<0.001$ and $^{****}p<0.0001$.

RESULTS

1) Effects of physiological aging on GLO1 activity and protein expression in 3 to 30-month-old WT mice

To investigate effect of physiological aging on GLO1 activity, we used WT mice of age: 3-30 months (n=5/age group). Spectrophotometric measurement of GLO1 enzyme activity revealed significantly increased GLO1 activity in the brains of 12 months old WT mice compared with WT mice at 3 and 6 months of age (Fig. 1A and C). We also found that beyond the age of 12 months, GLO1 activity significantly reduced up to 30 months of age (Fig. 1A and C). We observed that at 12 months of age, GLO1 activity increases with increase in total protein concentration (Fig.1B). Thus, we found that physiological aging contributes to significant decrease in GLO1 activity beyond 12 months. Thus, for uniformity, we used 12 months old mice for further experiments (except in case of RO mice).

2) Effects of global RAGE knockout on GLO1 activity and protein expression in 6- and 12-months old mice

In view of elevated expression of RAGE and reduced expression of GLO1 correlating to the severity of AD, we sought to detect the effect of RAGE on GLO1 activity and protein expression levels in RO mice. 6 month and 12-month-old homozygous RO mice were used (n=4-5/ genotype/age group). Spectrophotometric measurement of GLO1 enzyme activity revealed significantly increased GLO1 activity in the brains of RO mice compared with WT mice at 6 months (Fig. 2A) and 12 months of age (Fig. 3A). For 12- months- old RO mice, immunoblotting and quantification of GLO1 protein bands (Fig. 3B and 3C) revealed that the protein levels were significantly increased in RO mice compared with those of 12-months-old WT mice. But this effect

was not seen in 6 months old mice (Fig. 2B and 2C). Global deletion of RAGE contributes to increase in GLO1 activity in 6- and 12-months old mice and expression in 12 months old mice.

3) Effects of neuronal RAGE knockout on GLO1 activity and protein expression in 12-month old mice

Since RAGE is expressed in both neuronal and non-neuronal cells, we sought to detect the effect of conditional neuronal RAGE deletion on GLO1 activity and protein expression levels in homozygous nRKO mice. These nRKO mice were used along with age-matched WT controls. Spectrophotometric measurement of GLO1 enzyme activity revealed significantly increased GLO1 activity in the brains of nRKO mice compared with WT mice at 12 months of age (Fig. 4A). Immunoblotting and quantification of GLO1 protein bands (Fig. 4C) revealed that the protein levels were not increased significantly in nRKO mice compared with those of WT mice at 12 months of age (Fig. 4B and 4C). Unlike 12-months-old RO mice, nRKO mice did not show elevated GLO1 protein levels. This effect can be attributed to the specific cell types in which RAGE knockout was carried out. Here, we found that neuronal deletion of RAGE significantly contributes to increase in GLO1 activity but not protein expression.

4) Effects of neuronal DNRAGE mutant on GLO1 activity and protein expression in 12-month old mice

Since we found that RAGE deletion leads to increase in GLO1 activity and protein expression, we wanted to investigate the effect of neuronal DNRAGE on GLO1 activity and protein expression levels. Heterozygous neuronal DNRAGE (n=3-6/ genotype) mice were used along with age-matched WT controls. Spectrophotometric measurement of GLO1 enzyme activity revealed

significantly increased GLO1 activity in the brains of neuronal DNRAGE mice compared with WT mice at 12 months of age (Fig. 5A). Immunoblotting and quantification of GLO1 protein bands (Fig. 5B) revealed that the protein levels were not increased significantly in these mice compared with those of WT mice at 12 months of age (Fig. 5C). This pointed out the need to repeat the study in a higher number of experimental mice to confirm the results. Thus, we found that loss of signaling of neuronal RAGE significantly elevates GLO1 activity but not protein expression.

5) Effects of microglial DNMSR mutant on GLO1 activity and protein expression in 12 months old mice

As microglia have been implicated in the possible pathway of effect of RAGE in AD progression, we wanted to investigate the effect of microglial DNMSR mutant on GLO1 activity and protein expression levels. Heterozygous DNMSR (n=4/ genotype) mice were used along with age-matched WT controls. Spectrophotometric measurement of GLO1 enzyme activity revealed significantly increased GLO1 activity in the brains of microglial DNRAGE mice compared with WT mice at 12 months of age (Fig. 6A). Immunoblotting and quantification of GLO1 protein bands (Fig. 6B) revealed that the protein levels were not significantly increased in these mice compared with those of WT mice at 12 months of age (Fig. 6C). Thus, we found that loss of signaling of RAGE specifically in microglia significantly upregulates GLO1 activity but not protein expression.

6) Effects of mutant APP overexpression on GLO1 activity and protein expression in 12 months old mice

After checking the GLO1 activity and expression in the RAGE knockout and DNRAGE mouse models, we then determined whether RAGE had a direct role in modulating GLO1 activity and expression in mAPP mice overexpressing mutant APP/Aβ and the effect of deletion of RAGE in these mice.

Homozygous RAGE null mice (RO mice) were crossed with mAPP mice overexpressing mutant APP/Aβ to generate mAPP/RO mice (n=5/ genotype). We demonstrated that GLO1 activity and protein levels were significantly reduced in mAPP mice compared with WT mice. In contrast, GLO1 activity was found to be higher in both heterozygous mAPP/RO and homozygous RO mice due to global genetic deletion of RAGE (Fig. 7A).

Consistent with the enzyme activity results, immunoblotting and quantification of GLO1 protein bands (Fig. 7B and 7C) revealed that the protein levels were increased in both mAPP/RO and RO mice compared with those of mAPP mice at 12 months of age. Thus, global deletion of RAGE in mAPP/RO mice rescues the decrease in GLO1 activity and expression seen in mAPP mice.

In summary, we provide substantial evidence of the protective effect of deletion of RAGE or loss of RAGE signaling on GLO1 enzyme activity. Genetic deletion of RAGE and blocked RAGE signaling in cortical neurons or microglia blocks AGE-mediated downregulation of GLO1 enzyme activity.

The results of enzyme activity and western blot assay are summarized in Table 3.

Table 3: Summary of GLO1 activity and expression in various mouse models compared to WT

No.	Genotype	Genetic Manipulation	GLO1 activity	GLO1 expression
1	RO	Global RAGE knockout	Increased	Increased
2	nRKO	Neuronal RAGE knockout	Increased	Unchanged
3	Neuronal DNRAGE	Signal deficient mutant targeted to neurons	Increased	Unchanged
4	DNMSR	Signal deficient mutant targeted to microglia	Increased	Unchanged
5	mAPP	Overexpression of APP	Decreased	Decreased
6	mAPP/RO	mAPP crossed with RO	Increased	Increased

1A.



1B.



1C.



Figure 1: Effect of age on GLO1 enzyme activity in 3 to 30 months old WT mice.

(A)GLO1 enzyme activity was determined by spectrophotometric method in the cortex from 3 to 30-month-old WT mice (n=5/group) in an age-dependent manner at three different total protein concentrations [Two-way ANOVA with Tukey's post hoc multiple comparison tests, age: $F(3, 12) = 38.12$, concentration: $F(2, 3) = 114.2$ interaction: $F(8, 12) = 13.57$, $p<0.001$]. (B) Comparison of GLO1 activity at total protein concentration=2.5 and 5 ug at the age of 12 months (student's t test) (C)GLO1 activity of 3-30-month-old mice at total protein concentration=5 ug. (One-way ANOVA with Tukey's post hoc multiple comparison tests, $F(4, 10) = 225.7$ $P<0.0001$ *$p<0.05$, **$p<0.01$, ***$p<0.001$, ****$p<0.0001$)

2A.



2B.



2C.



2D.



Figure 2: Effect of global RAGE knockout on GLO1 enzyme activity and protein expression in 6 months old WT and RO mice.

(A) GLO1 enzyme activity was determined by spectrophotometric method in the cortex from 6-month-old WT and RAGE Knockout (RO) mice (n=4/ genotype) at total protein concentration= 5ug and (B) at increasing total protein concentration levels (Two-way ANOVA- concentration: $F(3, 8) = 182.1$, genotype: $F(1, 8) = 246.1$, $p<0.0001$, interaction: $F(3, 8) = 7.690$, $P=0.0096$). (C) GLO1 protein expression was demonstrated by quantifying intensity of immunoreactive bands of GLO1 in the brain homogenates from indicated mice. (n=4/group). Representative immunoblots show immunoreactive bands for GLO1(21kda) as well as β-Actin protein used as loading control. (D) Quantification of GLO1 immunoreactive bands was performed blots in triplicate. (Student's t-test, ns=non-significant)

3A.



3B.



3C.



Figure 3: Effect of global RAGE knockout on GLO1 enzyme activity and protein expression in 12 months old WT and RO mice.

(A)GLO1 enzyme activity was determined by spectrophotometric method in the cortex from 12-month-old WT and RAGE Knockout (RO) mice (n=5/group) in a time-dependent manner. [Two-way ANOVA with Tukey's post hoc test, time: $F (4, 40) = 1.235$, genotype: $F (1, 40) = 140.2$, interaction: $F (4, 40) = 2.1335$, $P<0.0001$)] (B)GLO1 protein expression was demonstrated by quantifying intensity of immunoreactive bands of GLO1 in the brain homogenates from indicated mice. (n=4-5/group). Representative immunoblots show immunoreactive bands for GLO1(21kda) as well as β-Actin protein used as loading control. (C) Quantification of GLO1 immunoreactive bands was performed for blots in triplicate. (Student's t-test, **$p<0.01$ for RO compared with WT)

4A.



4B.



4C.



Figure 4: Effect of neuronal RAGE knockout on GLO1 enzyme activity and protein expression in 12 months old WT and nRKO mice.

(A)GLO1 enzyme activity was determined by spectrophotometric method in the cortex from 12-month-old WT and nRKO mice (n=4-5/group) in time-dependent manner [Two-way ANOVA, genotype: $F (1, 35) = 257.1$, time: $F (4, 35) = 13.55$, interaction: $F (4, 35) = 0.2272$, $P<0.001$]. (B) GLO1 protein expression was demonstrated by quantifying intensity of immunoreactive bands of GLO1 in the brain homogenates from indicated mice (n=4-5/group). Representative immunoblots show immunoreactive bands for GLO1(21kda) as well as β-Actin protein used as loading control. (C) Quantification of GLO1 immunoreactive bands was performed for blots in triplicate (Student's t-test, ns=non-significant).

5A.



5B.



5C.



Figure 5: Effect of neuronal DNRAGE on GLO1 enzyme activity and protein expression in 12 months old WT and neuronal DNRAGE mice.

(A)GLO1 enzyme activity was determined by spectrophotometric method in the cortex from 12-month-old WT and neuronal DNRAGE mice (n=3-6/group) in time-dependent manner (Two-way ANOVA, time: $F (4, 50) = 0.01678$, genotype: $F (1, 50) = 89.30$, interaction: $F (4, 50) = 0.05961$, $P=0.0039$). (B)GLO1 protein expression was demonstrated by quantifying intensity of immunoreactive bands of GLO1 in the brain homogenates from indicated mice (n=4-5/group). Representative immunoblots show immunoreactive bands for GLO1(21kda) as well as β-Actin protein used as loading control. (C) Quantification of GLO1 immunoreactive bands was performed for blots in triplicate (Student's t-test, ns=non-significant).

6A.



6B.



6C.



Figure 6: Effect of DNMSR mutant on GLO1 enzyme activity and protein expression in 12 months old WT and DNMSR mice.

(A)GLO1 enzyme activity was determined by spectrophotometric method in the cortex from 12-month-old WT and DNMSR mice (n=4/group) in time-dependent manner (Two-way ANOVA, time: $F (4, 16) = 36.85$, genotype: $F (1, 4) = 74.33$, interaction: $F (4, 16) = 6.103$, $P<0.0001$). (B)GLO1 protein expression was demonstrated by quantifying intensity of immunoreactive bands of GLO1 in the brain homogenates from indicated mice (n=4-5/group). Representative immunoblots show immunoreactive bands for GLO1(21kda) as well as β-Actin protein used as loading control. (C) Quantification of GLO1 immunoreactive bands was performed for blots in triplicate (Student's t-test, ns=non-significant).

7A.



7B.



7C.



Figure 7: Effect of presence of mutant APP on GLO1 enzyme activity and protein expression in 12 months old WT, APP, APP/RO and RO mice.

(a)GLO1 enzyme activity was determined by spectrophotometric method in the cortex from indicated four genotypes of mice (n=5/group, age=12-15 months) in time-dependent manner [two-way ANOVA, genotype: $F(2, 3) = 163.1$, time: $F(3, 12) = 266.9$, interaction: $F(8, 12) = 0.5848$, $p<0.0001$]. (b)GLO1 protein expression was demonstrated by quantifying intensity of immunoreactive bands of GLO1 in the brain homogenates from indicated mice. (n=4-5/group). Representative immunoblots show immunoreactive bands for GLO1(21kda) as well as β-actin protein used as loading control. (c) quantification of GLO1 immunoreactive bands was performed for blots in triplicate (one-way ANOVA, Tukey's multiple comparison test, $F(3, 4) = 109.5$, $p=0.0003$, $^{**}p<0.01$, $^{***}p<0.001$ for RO compared with APP).

DISCUSSION

RAGE, a receptor for AGEs, is an immunoglobulin like cell surface receptor that is described as a pattern recognition receptor[3, 51, 55, 151]. RAGE is an important cellular co-factor for Aβ-mediated cellular changes relevant in pathogenesis of Alzheimer's disease. Interaction of RAGE with Aβ in neurons, microglia and vascular cells accelerates and exaggerates the detrimental effect on neuronal and synaptic function[42, 59, 81, 152]. RAGE-dependent signaling contributes to Aβ-mediated amyloid pathology and cognitive dysfunction observed in AD mouse model[3, 14, 28, 73, 85, 153-157]. On the other hand, RAGE deletion significantly attenuates neuronal and synaptic injury as previously shown[3, 28, 48]. RAGE inhibitors have been described previously to mitigate symptoms of AD[42, 57, 70, 158-160] and are found to be safe and effective orally in phase II clinical trials of AD[161].

MG is a major precursor of AGESs. As a metabolic byproduct continuously generated in vivo, MG can directly induce apoptosis[162-165] by generating oxidative stress. Moreover, MG is also found to be involved in the formation of Aβ and NFTs in AD[24, 31, 69, 166-173]. Furthermore, it is suggested that the decline in cognitive function in AD patients is closely related to the MG level as well as to the change in the glyoxalase system level or activity[23, 116, 122, 128, 174]. As one of the most important enzyme systems in vivo, the glyoxalase system exhibits detoxification of α-ketoaldehydes or dicarbonyl compounds including MG and glyoxal. However, the direct association between GLO1 and AD pathology still needed further exploration. Though various important signaling pathways possibly contribute to AD pathogenesis, here we focused our attention on the RAGE-signaling pathway.

Thus, the current study was designed to evaluate whether global deletion of RAGE along with the RAGE signaling blockade would have protective effects against changes in the GLO1 activity and protein expression due to AGEs-mediated disturbances and mAPP.

GLO1 enzyme activity is dependent on RAGE and is modulated in age-dependent manner.

Aging is characterized by physiological and functional deterioration across multiple organ systems. AGEs are found in abundance in the serum and accumulate in the tissues during normal aging. This accumulation is accelerated in pathological conditions such as diabetes and neurodegenerative diseases, such as AD[23, 59, 175]. Diabetes has been known to be a contributor to AD pathology[176, 177]. Increased levels of AGEs are reported in the cortical neurons of older adults and are linked to the severity of cognition impairment. The serum AGE levels are significantly increased in diabetic patients compared to healthy, non-diabetic controls. AGE-induced cellular perturbation and oxidative stress were blocked by antibodies to RAGE[178, 179]. Thus, increased levels of AGEs and RAGE play an important role in AGE-mediated cellular disturbances during the pathogenesis of aging-related disorders and diabetes.

To investigate the effects of physiological aging on GLO1 activity, we carried out an initial study in the WT mice of different ages. It is well supported in the literature that with increasing age, there is a consistent increase in the AGE levels which lead to RAGE-mediated changes in neuronal function which should lead to decrease in GLO1 activity according to our hypothesis [27, 100, 175, 180]. Corroborating that, we found significant decrease in the GLO1 activity of older WT mice compared to younger mice. We found that there was a slight increase in the activity from 3

months till the age of 12 months[100, 101] but beyond that, there was a significant reduction in GLO1 activity seen in 20- and 30-month old mice. These results support the minor elevation in GLO1 levels observed in young mice as reported in the previous literature[100, 101, 130]. Based on these preliminary studies, we used approximately 12-month-old mice for further comparative studies for uniformity and to remove the confounding factor of age.

Further, we wanted to look at the direct effect of genetic deletion of RAGE. Thus, we used previously generated RO mice. The spectrophotometric measurement of GLO1 enzyme activity revealed significantly increased GLO1 activity in RO mice compared with WT mice at 6 months and 12 months. In 12-month-old mice, the protein levels were significantly increased in RO mice compared with those of 12-month-old WT mice. But this effect was not observed in 6 months old mice. This difference in the effect can possibly be explained by the dissimilar changes seen in GLO1 levels in animals of different ages as found in the preliminary experiments in aging WT mice. This could be the effect of age on RAGE-modulated GLO1 expression and function.

RAGE is required both in neurons and microglia for regulating GLO1 activity.

Since RAGE is expressed in both neuronal and non-neuronal cells[14, 20, 27, 48, 54, 68, 69, 75, 80], the results from RO mice did not differentiate if the effect was due to a specific type of cell. Here, we wanted to look at the direct effect of other genetic manipulation of RAGE (conditional deletion or signaling blockade). Thus, we used two different previously generated transgenic mouse models: nRKO mouse model and DNMSR mouse model, to address the question of whether the activity of neuronal or microglial RAGE is responsible for AGE-induced reduction in GLO1.

We studied GLO1 activity and protein levels in these nRKO and DNMSR mice. These experiments revealed significantly increased GLO1 activity in the brains of both nRKO and DNMSR mice compared with age-matched WT control mice. The protein levels were slightly increased compared with those of WT mice, but the change was not statistically significant.
These results showed that absence of RAGE in both types of cells resulted in similar effect indicating that RAGE is required in both neuronal and microglial cells to modulate GLO1 activity. But these similar results do not necessarily point to a similar signaling mechanism.

Use of both global and neuronal knockout mice differs from cell-type specific DNRAGE mice. In case of DNRAGE mice, only the cytosolic tail is absent from the receptor leading to loss of signaling whereas for RAGE knockout mice, there is complete absence of receptor from the cell membrane. Thus, in case of DNRAGE mice, the receptor is available to bind ligands and modify them and reduce the unbound ligands from the extracellular fluid. That is not the case for knockout mice. Also, dimerization of RAGE is thought to be key for its signaling and other biological effects[181, 182], which is not possible in case of RAGE knockout.

To address this issue if the results seen in DNRAGE mice are due to sequestration of ligands (which is not possible in knockout mice), we further used neuronal DNRAGE mice. We found that neuronal DNRAGE mutation significantly upregulated GLO1 activity but did not alter protein expression, which is similar to the effect seen in earlier 2 models (nRKO and DNMSR). There were anomalies seen in the protein levels from western blot. Since the trend observed was of an increase in protein levels, we need to further increase the number of mice and repeat the

experiments to confirm the results. From these observations, we concluded that the effect in DNRAGE is not due to the difference between sequestration of ligands with the receptor. These results also show that the mechanism by which RAGE affects GLO1 activity and expression is similar for both types of cells. So, RAGE is an important modulator of GLO1 regardless of the cell type.

GLO1 protein levels are not altered in mice with cell-type specific RAGE mutations.

From the above experiments, we found that though RAGE deletion or DNRAGE leads to increased GLO1 enzyme activity in both global knockout and other 3 models, the protein levels are affected differently.

This difference can possibly be explained by various factors such as:

a) Difference in post-translational modification (PTM). GLO1 undergoes 4 different types of modifications namely (i) removal of the n-terminal methionine 1, (ii) n-terminal acetylation at alanine 2, (iii) a vicinal disulfide bridge between cysteine residues 19 and 20, and (iv) a mixed disulfide bond formed by reaction between thiolate of glutathione and disulfide bond of cysteine 139. MG also leads to PTM of proteins. Disulfide bridge formation impacts the enzyme activity while not impacting protein levels or enzyme stability. Different genotypes will possibly express different PTMs. So, if this particular modification i.e. disulfide bond formation occurs in the genotype, then it might be the reason of the higher enzyme activity but no change in protein levels[183].
b) Inherently, there can be differences in the conformation of the enzyme which may lead to variable binding causing the different effect on protein levels. This can also occur in case

of protein denaturation where the protein loses its function, which might lead to the protein levels to be lower or different. Since, the WT and Tg mice have similar conformation (being littermates), it possibly leads to insignificant difference/changes in protein levels.

c) For all the experiments, brain cortex homogenate was used. Thus, the homogenate contained both neuronal and non-neuronal cells. For cell-type specific mutants, some of the other cells in the homogenate without the knockout carried the intact RAGE exerting its effect, thus incomplete RAGE suppression may occur. This can possibly lead to no significant increase in the protein levels unlike the clear increase seen in the case of complete knockout models (RO and APP/RO).

d) In a yeast *Schizosaccharomyces pombe*, GLO1 activity is regulated in response to osmotic stress. But there is no change in mRNA or protein levels. This can be the case in mammalian GLO1 modulation as well[184]. In case of the experimental mice, different genotypes (WT and Tg) will experience different levels of osmotic stress which will cause enzyme activity to change but it might not affect the protein levels.

e) MG induces protein modification such as glycation which causes partial unfolding and thus, forms unstable proteins which degrade over time. This denaturation may cause non-significant differential change in the protein levels[185, 186]. Different degrees of denaturation might occur in animals based on gender and genotype. This will lead to differential influence on the protein levels. This might be the reason why we saw a variable degree of change in protein levels across multiple animal models.

f) The methods used such as enzyme activity assay and western blotting have different sensitivity to the GLO1 protein levels or activity measured during the experiments. In case of western blotting, the method measures the amount of static protein present in the cell

sample. In enzyme activity assay, the change in the OD measured tells us about the rate at which the enzyme reacts with the substrate and converts it to the product. In enzyme activity, the substrate binds to the enzyme leading to a signaling cascade which leads to signal amplification. This might be the main reason for the differences seen between the two methods, where we saw an increase in enzyme activity but no significant change in protein levels.

g) Gender differences and other variability among the mice. In literature, it has been found that there are sex differences in brain function, molecular changes and neurogenesis. Since our study included both male and female mice in different numbers (for each group), it is possible that the cumulative gender difference plays a role in the differential effect on protein expression [187]. It is also possible that an animal expresses higher or lower amount of protein leading to the different result.

APP mutation regulates GLO1 activity and protein level through RAGE signaling.

Amyloid plaques are characteristic lesions found in Alzheimer's disease (AD) and are composed of Aβ derived from APP [188]. Aβ formation involves sequential proteolytic cleavage of APP by β and γ-secretases [189-192]. β -secretase mediates APP cleavage to form the amino (N)-terminus of Aβ and yields the membrane bound C-terminal fragment CTFβ [190]. Next, γ-secretase cleaves CTFβ to release Aβ peptide and APP intracellular C-terminal domain (AICD), a 6-KD peptide also called CTFγ .

AGE accumulation has been demonstrated in senile plaques in different cortical areas such as entorhinal cortex[20, 75] and glial cells of AD brain [193]. We have previously published about RAGE-mediated Aβ accumulation in a mouse model of AD which was via modulation of β and γ-secretase activity through activation of GSK3β and P38 MAP kinase[28]. It has been demonstrated in vitro that aggregation of Aβ is significantly accelerated by AGE-mediated crosslinking[194]. Thus, AGEs may be one of the factors which accelerate Aβ deposition and plaque formation in AD[195].

Our previous studies demonstrated that increased cellular RAGE causes more Aβ-mediated perturbation in patients with AD and in an AD mouse model[3, 11, 13, 28, 155, 196, 197]. The literature mentions RAGE-dependent signaling in microglia contributes to neuroinflammation [74, 75]. However, deletion or selective deficiency of neuronal or microglial RAGE signaling by DNRAGE in the AD mouse model attenuated deterioration induced by AGEs or mAPP[21, 28]. It was also found that blockade of microglial RAGE is beneficial for Aβ-mediated neuronal changes [20, 69, 73].

We sought to study whether RAGE had a direct role in modulating GLO1 activity and expression in mAPP mice overexpressing mutant APP/Aβ (mAPP). We also determined the effect of deletion of RAGE in these mice(mAPP/RO). Tg mAPP (Swedish mutation: APP KM670/671NL, V717F) mouse model is a well-established animal model for AD. We demonstrated that GLO1 activity and protein levels were significantly reduced in homozygous mAPP mice compared with WT mice. In contrast, GLO1 activity was found to be higher in both heterozygous mAPP/RO and homozygous RO mice with global genetic deletion of RAGE. These effects seen in mAPP/RO

mice show that RAGE deletion has a protective effect against the downregulation of GLO1 activity seen in mAPP mice. Consistent with the enzyme activity results, the protein levels were also increased in both mAPP/RO and RO mice compared with those of 12-months-old mAPP mice.

Here, due to the presence of mutant APP in case of mAPP mice, the activity and protein levels decreased compared to WT controls. This mutation leads to overexpression of APP, which in turn leads to accelerated formation of Aβ. This Aβ formation causes plaque formation with increasing age. Since Aβ is known to bind to RAGE[14, 67, 151], this interaction causes RAGE-mediated signaling which leads to decrease in the GLO1 activity. In contrast, due to global knockout in RO and mAPP/RO mice, the activity and protein levels both showed significant improvement compared to mAPP mice. Thus, we concluded that global deletion of RAGE in mAPP/RO mice rescued the decrease in GLO1 activity and expression seen in mAPP mice.

Possible mechanism for effect of AGEs-RAGE interaction on GLO1 activity can be through multiple pathways such as formation of reactive oxygen species (ROS) leading to oxidative stress, activation of PI3K-AKT pathway [76] and stimulation of P38 or ERK signaling[66]. All these activations lead to upregulation of NF-κB, which is known to be involved in inflammation, DNA transcription and cytokine production[81, 106]. This NF-κB upregulation leads to pro-inflammatory cytokine release causing neuroinflammation, which is one of the major changes seen in case of AD. It has also been reported that NF-κB regulates APP and β and γ-secretases[198]. These pro-inflammatory changes might lead to downregulation of GLO1 activity[59].

So, to summarize, enzyme activity assay and western blot analysis indicated that in comparison to healthy controls, GLO1 activity and protein levels decreased with age and in the presence of mAPP expression. In transgenic non-AD models where RAGE was deleted or signaling was blocked, GLO1 enzyme activity increased though there was variable effect regarding the GLO1 protein levels possibly due to various factors discussed above.

The data presented herein clearly demonstrates, that genetic deletion of RAGE or loss of RAGE signaling significantly increased GLO1 activity in the four transgenic and mAPP mouse models. The GLO1 protein expression also increased in case of RO and mAPP/RO mice. Using our novel transgenic mouse models with RAGE deletion or conditional DNRAGE mutant for this evaluation, we provide convincing evidence to support the effects of AGEs–RAGE interaction on GLO1 enzyme activity and protein expression.

Our findings also suggest that RAGE is a strong potential target to limit AGEs-induced perturbations, which is in accordance with previous literature [3, 19, 28, 63, 72, 73, 79, 82, 153, 199, 200]. Also, the decrease of GLO1 expression with increasing age and pathology might be one reason for AGE or MG-induced neuronal impairment, apoptosis, and AGE formation in plaques and NFTs seen in AD. Thus, GLO1 appears to be an important enzyme target for protection against RAGE-mediated signaling[140, 201, 202]. So, restoring or enhancing GLO1 activity can provide new opportunities for AD treatment.

Several strategies, to prevent the AGEs-induced disturbances, are described in literature such as enhancement of GLO1 activity[108, 112, 114, 118, 119, 132-134, 203, 204], use of RAGE inhibitors [11, 57, 61, 124, 127, 160, 200, 205], inhibition of MG toxic reactions by using AGE antagonists[23, 127] which are antioxidants[133, 206] and decreasing glycation activity by using anti-diabetic drugs[16, 207-211]. All these approaches lead to direct or indirect enhancement or restoration of GLO1 activity. They are also efficient in alleviating some AD symptoms such as cognitive impairment and neuroinflammation.

Our study was a simple attempt at correlating certain factors such as RAGE in AD to the MG-detoxification process in the brain through the glyoxalase system. There are certain limitations to our studies because it may not be possible to always extrapolate animal data to humans since animal models are not a perfect predictor of human physiological or pathological conditions. There also needs to be a further extensive study in clinical settings as well as other animal models to have a better in vivo-in vitro correlation. We need a detailed study of significance of GLO1 enzyme activity using GLO1 genetic manipulations such as mice exhibiting GLO1 knockout or GLO1 overexpression [126].

To conclude, we show that GLO1 is directly upregulated by RAGE deletion or signaling blockade but the exact role of glyoxalase system in the AD pathogenesis and involved signaling pathways such as MAPK need further investigation. Also, GLO1 is downregulated in case of mAPP mutation featuring overproduction of Aβ. Blockade of AGEs-RAGE axis by genetic deletion of RAGE and by use of DNRAGE protects against this downregulation of GLO1 activity and further neurodegenerative changes seen in diseases such as AD.

Thus, it will be very crucial and valuable to further study the significance of glyoxalase system which will contribute to a better understanding of AD pathogenesis, as well as find new therapies for AD.

REFERENCES

1. Van Cauwenberghe, C., C. Van Broeckhoven, and K. Sleegers, *The genetic landscape of Alzheimer disease: clinical implications and perspectives.* Genet Med, 2016. **18**(5): p. 421-30.
2. Raskin, J., et al., *Neurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions.* Current Alzheimer research, 2015. **12**(8): p. 712-722.
3. Yan, S.S., et al., *RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer's disease.* Front Biosci (Schol Ed), 2012. **4**: p. 240-50.
4. Wang, Z., et al., *Identifying circRNA-associated-ceRNA networks in the hippocampus of Aβ1-42-induced Alzheimer's disease-like rats using microarray analysis.* Aging, 2018. **10**(4): p. 775-788.
5. Pugazhenthi, S., L. Qin, and P.H. Reddy, *Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease.* Biochim Biophys Acta Mol Basis Dis, 2017. **1863**(5): p. 1037-1045.
6. Benedict, C. and C.A. Grillo, *Insulin Resistance as a Therapeutic Target in the Treatment of Alzheimer's Disease: A State-of-the-Art Review.* Frontiers in Neuroscience, 2018. **12**.
7. Frost, J.L., et al., *Pyroglutamate-3 amyloid-beta deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models.* Am J Pathol, 2013. **183**(2): p. 369-81.
8. Salas, I.H., et al., *High fat diet treatment impairs hippocampal long-term potentiation without alterations of the core neuropathological features of Alzheimer disease.* Neurobiol Dis, 2018. **113**: p. 82-96.
9. Serrano-Pozo, A., et al., *Neuropathological alterations in Alzheimer disease.* Cold Spring Harb Perspect Med, 2011. **1**(1): p. a006189.
10. Van Eldik, L.J., et al., *The roles of inflammation and immune mechanisms in Alzheimer's disease.* Alzheimers Dement (N Y), 2016. **2**(2): p. 99-109.
11. Perrone, L., et al., *The Complexity of Sporadic Alzheimer's Disease Pathogenesis: The Role of RAGE as Therapeutic Target to Promote Neuroprotection by Inhibiting Neurovascular Dysfunction.* Int J Alzheimers Dis, 2012. **2012**: p. 734956.
12. Leclerc, E., E. Sturchler, and S.W. Vetter, *The S100B/RAGE Axis in Alzheimer's Disease.* Cardiovasc Psychiatry Neurol, 2010. **2010**: p. 539581.
13. Kojro, E. and R. Postina, *Regulated proteolysis of RAGE and AbetaPP as possible link between type 2 diabetes mellitus and Alzheimer's disease.* J Alzheimers Dis, 2009. **16**(4): p. 865-78.
14. Sparvero, L.J., et al., *RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation.* Journal of Translational Medicine, 2009. **7**(1): p. 17.
15. Hall, A.M. and E.D. Roberson, *Mouse models of Alzheimer's disease.* Brain Res Bull, 2012. **88**(1): p. 3-12.
16. Markowicz-Piasecka, M., et al., *Metformin – a Future Therapy for Neurodegenerative Diseases.* Pharmaceutical Research, 2017. **34**(12): p. 2614-2627.
17. Deane, R.J., *Is RAGE still a therapeutic target for Alzheimer's disease?* Future Med Chem, 2012. **4**(7): p. 915-25.
18. Diehl, T., R. Mullins, and D. Kapogiannis, *Insulin resistance in Alzheimer's disease.* Translational Research, 2017. **183**: p. 26-40.
19. Miller, M.C., et al., *Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease.* Brain Res, 2008. **1230**: p. 273-80.
20. Criscuolo, C., et al., *Entorhinal Cortex dysfunction can be rescued by inhibition of microglial RAGE in an Alzheimer's disease mouse model.* Sci Rep, 2017. **7**: p. 42370.

21. Du, H., et al., *Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model.* Proc Natl Acad Sci U S A, 2010. **107**(43): p. 18670-5.
22. Batkulwar, K., et al., *Advanced Glycation End Products Modulate Amyloidogenic APP Processing and Tau Phosphorylation: A Mechanistic Link between Glycation and the Development of Alzheimer's Disease.* ACS Chem Neurosci, 2018. **9**(5): p. 988-1000.
23. Rabbani, N., M. Xue, and P.J. Thornalley, *Methylglyoxal-induced dicarbonyl stress in aging and disease: first steps towards glyoxalase 1-based treatments.* Clin Sci (Lond), 2016. **130**(19): p. 1677-96.
24. Takeuchi, M. and S. Yamagishi, *Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease.* J Alzheimers Dis, 2009. **16**(4): p. 845-58.
25. Byun, K., et al., *Advanced glycation end-products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases.* Pharmacol Ther, 2017. **177**: p. 44-55.
26. Sharaf, H., et al., *Advanced glycation endproducts increase proliferation, migration and invasion of the breast cancer cell line MDA-MB-231.* Biochim Biophys Acta, 2015. **1852**(3): p. 429-41.
27. Srikanth, V., et al., *Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.* Neurobiol Aging, 2011. **32**(5): p. 763-77.
28. Fang, F., et al., *RAGE mediates Abeta accumulation in a mouse model of Alzheimer's disease via modulation of beta- and gamma-secretase activity.* Hum Mol Genet, 2018. **27**(6): p. 1002-1014.
29. Lauretti, E. and D. Pratico, *Glucose deprivation increases tau phosphorylation via P38 mitogen-activated protein kinase.* Aging Cell, 2015. **14**(6): p. 1067-74.
30. Tan, X., et al., *Ginseng improves cognitive deficit via the RAGE/NF-κB pathway in advanced glycation end product-induced rats.* Journal of Ginseng Research, 2015. **39**(2): p. 116-124.
31. Karran, E. and B. De Strooper, *The amyloid cascade hypothesis: are we poised for success or failure?* J Neurochem, 2016. **139 Suppl 2**: p. 237-252.
32. Zhao, J., et al., *The Role of MicroRNAs in Aβ Deposition and Tau Phosphorylation in Alzheimer's Disease.* Frontiers in Neurology, 2017. **8**.
33. Yoshida, H. and M. Goedert, *Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4/p38delta or JNK2 in the presence of heparin generates the AT100 epitope.* J Neurochem, 2006. **99**(1): p. 154-64.
34. Yao, J., et al., *Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease.* J Neurosci, 2011. **31**(6): p. 2313-20.
35. Thal, D.R. and M. Fandrich, *Protein aggregation in Alzheimer's disease: Abeta and tau and their potential roles in the pathogenesis of AD.* Acta Neuropathol, 2015. **129**(2): p. 163-5.
36. Tenreiro, S., K. Eckermann, and T.F. Outeiro, *Protein phosphorylation in neurodegeneration: friend or foe?* Front Mol Neurosci, 2014. **7**: p. 42.
37. Sturchler-Pierrat, C., et al., *Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology.* Proc Natl Acad Sci U S A, 1997. **94**(24): p. 13287-92.
38. Regan, P., et al., *Tau phosphorylation at serine 396 residue is required for hippocampal LTD.* J Neurosci, 2015. **35**(12): p. 4804-12.
39. Panza, F., et al., *Emerging drugs to reduce abnormal beta-amyloid protein in Alzheimer's disease patients.* Expert Opin Emerg Drugs, 2016. **21**(4): p. 377-391.
40. Morris, M., et al., *The many faces of tau.* Neuron, 2011. **70**(3): p. 410-26.
41. Yamagishi, S., T. Matsui, and K. Nakamura, *Blockade of the advanced glycation end products (AGEs) and their receptor (RAGE) system is a possible mechanism for sustained beneficial effects*

of multifactorial intervention on mortality in type 2 diabetes. Med Hypotheses, 2008. **71**(5): p. 749-51.
42. Xie, J., et al., *Cellular signalling of the receptor for advanced glycation end products (RAGE).* Cell Signal, 2013. **25**(11): p. 2185-97.
43. Wendt, T.M., et al., *RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy.* Am J Pathol, 2003. **162**(4): p. 1123-37.
44. Wang, S.-Y., et al., *Qifu-Yin attenuates AGEs-induced Alzheimer-like pathophysiological changes through the RAGE/NF-κB pathway.* Chinese Journal of Natural Medicines, 2014. **12**(12): p. 920-928.
45. Thornalley, P.J., *Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs.* Cell Mol Biol (Noisy-le-grand), 1998. **44**(7): p. 1013-23.
46. Thornalley, P.J., *Dietary AGEs and ALEs and risk to human health by their interaction with the receptor for advanced glycation endproducts (RAGE)--an introduction.* Mol Nutr Food Res, 2007. **51**(9): p. 1107-10.
47. Takeuchi, M., et al., *Involvement of Advanced Glycation End-products (AGEs) in Alzheimers Disease.* Current Alzheimer Research, 2004. **1**(1): p. 39-46.
48. Zhang, H., et al., *Genetic deficiency of neuronal RAGE protects against AGE-induced synaptic injury.* Cell Death Dis, 2014. **5**: p. e1288.
49. Brett, J., et al., *Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues.* Am J Pathol, 1993. **143**(6): p. 1699-712.
50. Lue, L., et al., *Preventing Activation of Receptor for Advanced Glycation Endproducts in Alzheimers Disease.* Current Drug Target -CNS & Neurological Disorders, 2005. **4**(3): p. 249-266.
51. Yan, S.D., et al., *RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation?* J Alzheimers Dis, 2009. **16**(4): p. 833-43.
52. Zhou, Z., et al., *Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes.* J Neuroinflammation, 2017. **14**(1): p. 75.
53. Zhu, H. and Q. Ding, *Lower expression level of two RAGE alternative splicing isoforms in Alzheimer's disease.* Neurosci Lett, 2015. **597**: p. 66-70.
54. Ding, Q. and J.N. Keller, *Evaluation of rage isoforms, ligands, and signaling in the brain.* Biochim Biophys Acta, 2005. **1746**(1): p. 18-27.
55. Bongarzone, S., et al., *Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective.* J Med Chem, 2017. **60**(17): p. 7213-7232.
56. Maczurek, A., K. Shanmugam, and G. Munch, *Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer's disease.* Ann N Y Acad Sci, 2008. **1126**: p. 147-51.
57. Sanajou, D., et al., *AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions.* Eur J Pharmacol, 2018. **833**: p. 158-164.
58. de Vos, L.C., et al., *Advanced glycation end products: An emerging biomarker for adverse outcome in patients with peripheral artery disease.* Atherosclerosis, 2016. **254**: p. 291-299.
59. Ramasamy, R., et al., *Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation.* Glycobiology, 2005. **15**(7): p. 16r-28r.
60. Lander, H.M., et al., *Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress.* J Biol Chem, 1997. **272**(28): p. 17810-4.
61. Ott, C., et al., *Role of advanced glycation end products in cellular signaling.* Redox Biol, 2014. **2**: p. 411-29.

62. Yan, S.F., et al., *The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications.* Curr Diab Rep, 2007. **7**(2): p. 146-53.
63. Yan, S.D., et al., *RAGE-Abeta interactions in the pathophysiology of Alzheimer's disease.* Restor Neurol Neurosci, 1998. **12**(2-3): p. 167-73.
64. Yan, S.D., et al., *RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease.* Nature, 1996. **382**(6593): p. 685-91.
65. Sorci, G., et al., *RAGE in tissue homeostasis, repair and regeneration.* Biochim Biophys Acta, 2013. **1833**(1): p. 101-9.
66. Origlia, N., et al., *Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction.* J Neurosci, 2008. **28**(13): p. 3521-30.
67. Lee, E.J. and J.H. Park, *Receptor for Advanced Glycation Endproducts (RAGE), Its Ligands, and Soluble RAGE: Potential Biomarkers for Diagnosis and Therapeutic Targets for Human Renal Diseases.* Genomics Inform, 2013. **11**(4): p. 224-9.
68. Hudson, B.I., et al., *Identification, classification, and expression of RAGE gene splice variants.* FASEB J, 2008. **22**(5): p. 1572-80.
69. Choi, B.R., et al., *Increased expression of the receptor for advanced glycation end products in neurons and astrocytes in a triple transgenic mouse model of Alzheimer's disease.* Exp Mol Med, 2014. **46**: p. e75.
70. Chen, J., et al., *Inhibition of AGEs/RAGE/Rho/ROCK pathway suppresses non-specific neuroinflammation by regulating BV2 microglial M1/M2 polarization through the NF-kappaB pathway.* J Neuroimmunol, 2017. **305**: p. 108-114.
71. Bucciarelli, L.G., et al., *RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice.* Circulation, 2002. **106**(22): p. 2827-35.
72. Arancio, O., et al., *RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice.* EMBO J, 2004. **23**(20): p. 4096-105.
73. Fang, F., et al., *RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease.* Faseb j, 2010. **24**(4): p. 1043-55.
74. Yu, Y. and R.D. Ye, *Microglial Abeta receptors in Alzheimer's disease.* Cell Mol Neurobiol, 2015. **35**(1): p. 71-83.
75. Origlia, N., et al., *Microglial receptor for advanced glycation end product-dependent signal pathway drives beta-amyloid-induced synaptic depression and long-term depression impairment in entorhinal cortex.* J Neurosci, 2010. **30**(34): p. 11414-25.
76. Dukic-Stefanovic, S., et al., *Signal transduction pathways in mouse microglia N-11 cells activated by advanced glycation endproducts (AGEs).* J Neurochem, 2003. **87**(1): p. 44-55.
77. Munch, G., et al., *Microglial activation induces cell death, inhibits neurite outgrowth and causes neurite retraction of differentiated neuroblastoma cells.* Exp Brain Res, 2003. **150**(1): p. 1-8.
78. Caspersen, C., et al., *Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease.* FASEB J, 2005. **19**(14): p. 2040-1.
79. Tuppo, E.E. and H.R. Arias, *The role of inflammation in Alzheimer's disease.* Int J Biochem Cell Biol, 2005. **37**(2): p. 289-305.
80. Origlia, N., et al., *RAGE inhibition in microglia prevents ischemia-dependent synaptic dysfunction in an amyloid-enriched environment.* J Neurosci, 2014. **34**(26): p. 8749-60.
81. Angelo, M.F., et al., *The proinflammatory RAGE/NF-kappaB pathway is involved in neuronal damage and reactive gliosis in a model of sleep apnea by intermittent hypoxia.* PLoS One, 2014. **9**(9): p. e107901.

82. Takuma, K., et al., *RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction.* Proc Natl Acad Sci U S A, 2009. **106**(47): p. 20021-6.
83. Zhang, J., et al., *Long-term treadmill exercise attenuates Abeta burdens and astrocyte activation in APP/PS1 mouse model of Alzheimer's disease.* Neurosci Lett, 2018. **666**: p. 70-77.
84. Xue, J., et al., *The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGEs.* Biochemistry, 2014. **53**(20): p. 3327-35.
85. Deane, R., et al., *RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain.* Nat Med, 2003. **9**(7): p. 907-13.
86. Maessen, D.E., C.D. Stehouwer, and C.G. Schalkwijk, *The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases.* Clin Sci (Lond), 2015. **128**(12): p. 839-61.
87. Kalapos, M.P., *The tandem of free radicals and methylglyoxal.* Chem Biol Interact, 2008. **171**(3): p. 251-71.
88. Sousa Silva, M., et al., *The glyoxalase pathway: the first hundred years… and beyond.* Biochemical Journal, 2013. **453**(1): p. 1-15.
89. Rabbani, N. and P.J. Thornalley, *Glyoxalase in diabetes, obesity and related disorders.* Seminars in Cell & Developmental Biology, 2011. **22**(3): p. 309-317.
90. Xue, M., N. Rabbani, and P.J. Thornalley, *Glyoxalase in ageing.* Semin Cell Dev Biol, 2011. **22**(3): p. 293-301.
91. Thornalley, P.J., *Glyoxalase I – structure, function and a critical role in the enzymatic defence against glycation.* Biochemical Society Transactions, 2003. **31**(6): p. 1343-1348.
92. Thornalley, P.J., *Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options.* Int Rev Neurobiol, 2002. **50**: p. 37-57.
93. Rabbani, N., et al., *Multiple roles of glyoxalase 1-mediated suppression of methylglyoxal glycation in cancer biology-Involvement in tumour suppression, tumour growth, multidrug resistance and target for chemotherapy.* Semin Cancer Biol, 2018. **49**: p. 83-93.
94. Rabbani, N. and P.J. Thornalley, *Glyoxalase 1 Modulation in Obesity and Diabetes.* Antioxid Redox Signal, 2018.
95. Angeloni, C., et al., *Neuroprotective Effect of Sulforaphane against Methylglyoxal Cytotoxicity.* Chemical Research in Toxicology, 2015. **28**(6): p. 1234-1245.
96. Angeloni, C., L. Zambonin, and S. Hrelia, *Role of Methylglyoxal in Alzheimer's Disease.* BioMed Research International, 2014. **2014**: p. 1-12.
97. Maher, P., *Methylglyoxal, advanced glycation end products and autism: Is there a connection?* Medical Hypotheses, 2012. **78**(4): p. 548-552.
98. Hambsch, B., *Altered glyoxalase 1 expression in psychiatric disorders: cause or consequence?* Semin Cell Dev Biol, 2011. **22**(3): p. 302-8.
99. Hambsch, B., et al., *Methylglyoxal-mediated anxiolysis involves increased protein modification and elevated expression of glyoxalase 1 in the brain.* J Neurochem, 2010. **113**(5): p. 1240-51.
100. Kuhla, B., et al., *Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains.* Neurobiol Aging, 2007. **28**(1): p. 29-41.
101. Kuhla, B., et al., *Age-dependent changes of glyoxalase I expression in human brain.* Neurobiology of Aging, 2006. **27**(6): p. 815-822.
102. Kuhla, B., et al., *Methylglyoxal, Glyoxal, and Their Detoxification in Alzheimer's Disease.* Annals of the New York Academy of Sciences, 2005. **1043**(1): p. 211-216.
103. Currais, A. and P. Maher, *Functional Consequences of Age-Dependent Changes in Glutathione Status in the Brain.* Antioxidants & Redox Signaling, 2013. **19**(8): p. 813-822.

104. Krautwald, M. and G. Münch, *Advanced glycation end products as biomarkers and gerontotoxins – A basis to explore methylglyoxal-lowering agents for Alzheimer's disease?* Experimental Gerontology, 2010. **45**(10): p. 744-751.
105. Thornalley, P.J., A. Langborg, and H.S. Minhas, *Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose.* Biochem J, 1999. **344 Pt 1**(1): p. 109-16.
106. Bierhaus, A., et al., *Advanced Glycation End Product-Induced Activation of NF- B is Suppressed by -Lipoic Acid in Cultured Endothelial Cells.* Diabetes, 1997. **46**(9): p. 1481-1490.
107. Thornalley, P.J., *Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors.* Chem Biol Interact, 1998. **111-112**: p. 137-51.
108. Shinohara, M., et al., *Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis.* J Clin Invest, 1998. **101**(5): p. 1142-7.
109. Ahmed, U., P.J. Thornalley, and N. Rabbani, *Possible role of methylglyoxal and glyoxalase in arthritis.* Biochem Soc Trans, 2014. **42**(2): p. 538-42.
110. Arai, M., et al., *Measurement of glyoxalase activities.* Biochem Soc Trans, 2014. **42**(2): p. 491-4.
111. Bangel, F.N., et al., *Genetic analysis of the glyoxalase system in schizophrenia.* Prog Neuropsychopharmacol Biol Psychiatry, 2015. **59**: p. 105-110.
112. Berner, A.K., et al., *Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology.* Diabetologia, 2012. **55**(3): p. 845-54.
113. Chaudhuri, J., et al., *A Caenorhabditis elegans Model Elucidates a Conserved Role for TRPA1-Nrf Signaling in Reactive alpha-Dicarbonyl Detoxification.* Curr Biol, 2016. **26**(22): p. 3014-3025.
114. Chen, F., et al., *Role for glyoxalase I in Alzheimer's disease.* Proc Natl Acad Sci U S A, 2004. **101**(20): p. 7687-92.
115. Dafre, A.L., et al., *Methylglyoxal, the foe and friend of glyoxalase and Trx/TrxR systems in HT22 nerve cells.* Free Radic Biol Med, 2015. **89**: p. 8-19.
116. Dafre, A.L., A.E. Schmitz, and P. Maher, *Methylglyoxal-induced AMPK activation leads to autophagic degradation of thioredoxin 1 and glyoxalase 2 in HT22 nerve cells.* Free Radic Biol Med, 2017. **108**: p. 270-279.
117. Distler, M.G., et al., *Glyoxalase 1 increases anxiety by reducing GABAA receptor agonist methylglyoxal.* J Clin Invest, 2012. **122**(6): p. 2306-15.
118. Frandsen, J.R. and P. Narayanasamy, *Neuroprotection through flavonoid: Enhancement of the glyoxalase pathway.* Redox Biol, 2018. **14**: p. 465-473.
119. Geoffrion, M., et al., *Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin-treated, apolipoprotein E-deficient mice.* Physiol Rep, 2014. **2**(6).
120. Germanova, A., et al., *Receptor for advanced glycation end products (RAGE) and glyoxalase I gene polymorphisms in pathological pregnancy.* Clin Biochem, 2012. **45**(16-17): p. 1409-14.
121. Hansen, F., et al., *Methylglyoxal Induces Changes in the Glyoxalase System and Impairs Glutamate Uptake Activity in Primary Astrocytes.* Oxid Med Cell Longev, 2017. **2017**: p. 9574201.
122. Hansen, F., et al., *Methylglyoxal can mediate behavioral and neurochemical alterations in rat brain.* Physiol Behav, 2016. **164**(Pt A): p. 93-101.
123. Holewinski, R.J. and D.J. Creighton, *Inhibition by active site directed covalent modification of human glyoxalase I.* Bioorg Med Chem, 2014. **22**(13): p. 3301-8.
124. Hollenbach, M., *The Role of Glyoxalase-I (Glo-I), Advanced Glycation Endproducts (AGEs), and Their Receptor (RAGE) in Chronic Liver Disease and Hepatocellular Carcinoma (HCC).* Int J Mol Sci, 2017. **18**(11).

125. Inagi, R., *RAGE and glyoxalase in kidney disease.* Glycoconj J, 2016. **33**(4): p. 619-26.
126. Jang, S., et al., *Generation and characterization of mouse knockout for glyoxalase 1.* Biochem Biophys Res Commun, 2017. **490**(2): p. 460-465.
127. Jiang, L., et al., *Role of the Glyoxalase System in Alzheimer's Disease.* J Alzheimers Dis, 2018. **66**(3): p. 887-899.
128. Koike, S., et al., *Age-related alteration in the distribution of methylglyoxal and its metabolic enzymes in the mouse brain.* Brain Res Bull, 2019. **144**: p. 164-170.
129. Krechler, T., et al., *Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer.* Clin Biochem, 2010. **43**(10-11): p. 882-6.
130. Kurz, A., et al., *Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress.* Cell Mol Life Sci, 2011. **68**(4): p. 721-33.
131. Lee, D.Y. and G.D. Chang, *Methylglyoxal in cells elicits a negative feedback loop entailing transglutaminase 2 and glyoxalase 1.* Redox Biol, 2014. **2**: p. 196-205.
132. Miyata, T., et al., *Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient.* Kidney Int, 2001. **60**(6): p. 2351-9.
133. More, S.S., A.P. Vartak, and R. Vince, *Restoration of glyoxalase enzyme activity precludes cognitive dysfunction in a mouse model of Alzheimer's disease.* ACS Chem Neurosci, 2013. **4**(2): p. 330-8.
134. Morgenstern, J., et al., *Loss of Glyoxalase 1 Induces Compensatory Mechanism to Achieve Dicarbonyl Detoxification in Mammalian Schwann Cells.* J Biol Chem, 2017. **292**(8): p. 3224-3238.
135. Navarrete Santos, A., et al., *Dicarbonyls induce senescence of human vascular endothelial cells.* Mech Ageing Dev, 2017. **166**: p. 24-32.
136. Nigro, C., et al., *Methylglyoxal-Glyoxalase 1 Balance: The Root of Vascular Damage.* Int J Mol Sci, 2017. **18**(1).
137. Nishimoto, S., et al., *Activation of Nrf2 attenuates carbonyl stress induced by methylglyoxal in human neuroblastoma cells: Increase in GSH levels is a critical event for the detoxification mechanism.* Biochem Biophys Res Commun, 2017. **483**(2): p. 874-879.
138. Rabbani, N. and P.J. Thornalley, *Dicarbonyl stress in cell and tissue dysfunction contributing to ageing and disease.* Biochem Biophys Res Commun, 2015. **458**(2): p. 221-6.
139. Rabbani, N. and P.J. Thornalley, *Advanced glycation end products in the pathogenesis of chronic kidney disease.* Kidney Int, 2018. **93**(4): p. 803-813.
140. Ramasamy, R., S.F. Yan, and A.M. Schmidt, *Advanced glycation endproducts: from precursors to RAGE: round and round we go.* Amino Acids, 2012. **42**(4): p. 1151-61.
141. Sakellariou, S., et al., *Clinical significance of AGE-RAGE axis in colorectal cancer: associations with glyoxalase-I, adiponectin receptor expression and prognosis.* BMC Cancer, 2016. **16**: p. 174.
142. Schalkwijk, C.G., *Vascular AGE-ing by methylglyoxal: the past, the present and the future.* Diabetologia, 2015. **58**(8): p. 1715-9.
143. Skrha, J., Jr., et al., *Fructosamine 3-kinase and glyoxalase I polymorphisms and their association with soluble RAGE and adhesion molecules in diabetes.* Physiol Res, 2014. **63 Suppl 2**: p. S283-91.
144. Takano, M., et al., *Proteomic analysis of the brain tissues from a transgenic mouse model of amyloid beta oligomers.* Neurochem Int, 2012. **61**(3): p. 347-55.
145. Xue, M., et al., *Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation.* Biochem J, 2012. **443**(1): p. 213-22.
146. Kosaka, T., et al., *RAGE, receptor of advanced glycation endoproducts, negatively regulates chondrocytes differentiation.* PLoS One, 2014. **9**(9): p. e108819.

147. Mucke, L., et al., *High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.* J Neurosci, 2000. **20**(11): p. 4050-8.
148. Du, H., et al., *Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease.* Nat Med, 2008. **14**(10): p. 1097-105.
149. Fang, D., et al., *Increased neuronal PreP activity reduces Abeta accumulation, attenuates neuroinflammation and improves mitochondrial and synaptic function in Alzheimer disease's mouse model.* Hum Mol Genet, 2015. **24**(18): p. 5198-210.
150. Fang, D., et al., *Increased Electron Paramagnetic Resonance Signal Correlates with Mitochondrial Dysfunction and Oxidative Stress in an Alzheimer's disease Mouse Brain.* J Alzheimers Dis, 2016. **51**(2): p. 571-80.
151. Fritz, G., *RAGE: a single receptor fits multiple ligands.* Trends Biochem Sci, 2011. **36**(12): p. 625-32.
152. Xue, J., et al., *Change in the Molecular Dimension of a RAGE-Ligand Complex Triggers RAGE Signaling.* Structure, 2016. **24**(9): p. 1509-22.
153. Chen, X., et al., *RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease.* Curr Mol Med, 2007. **7**(8): p. 735-42.
154. Donahue, J.E., et al., *RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease.* Acta Neuropathol, 2006. **112**(4): p. 405-15.
155. Cho, H.J., et al., *RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model.* FASEB J, 2009. **23**(8): p. 2639-49.
156. Ma, L., et al., *RAGE is expressed in pyramidal cells of the hippocampus following moderate hypoxic–ischemic brain injury in rats.* Brain Research, 2003. **966**(2): p. 167-174.
157. Mitchell, M.B., et al., *RAGE and Abeta immunoglobulins: relation to Alzheimer's disease-related cognitive function.* J Int Neuropsychol Soc, 2010. **16**(4): p. 672-8.
158. Braley, A., et al., *Regulation of Receptor for Advanced Glycation End Products (RAGE) Ectodomain Shedding and Its Role in Cell Function.* J Biol Chem, 2016. **291**(23): p. 12057-73.
159. Galasko, D., et al., *Clinical trial of an inhibitor of RAGE-A interactions in Alzheimer disease.* Neurology, 2014. **82**(17): p. 1536-1542.
160. Schmidt, A.M., et al., *Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis.* Circ Res, 1999. **84**(5): p. 489-97.
161. Cui, L., et al., *A Novel, Multi-Target Natural Drug Candidate, Matrine, Improves Cognitive Deficits in Alzheimer's Disease Transgenic Mice by Inhibiting Abeta Aggregation and Blocking the RAGE/Abeta Axis.* Mol Neurobiol, 2017. **54**(3): p. 1939-1952.
162. Gawlowski, T., et al., *AGEs and methylglyoxal induce apoptosis and expression of Mac-1 on neutrophils resulting in platelet—neutrophil aggregation.* Thrombosis Research, 2007. **121**(1): p. 117-126.
163. Prasad, K., *AGE–RAGE stress: a changing landscape in pathology and treatment of Alzheimer's disease.* Molecular and Cellular Biochemistry, 2019.
164. Sena, C.M., et al., *Methylglyoxal promotes oxidative stress and endothelial dysfunction.* Pharmacological Research, 2012. **65**(5): p. 497-506.
165. Seo, K., S.H. Ki, and S.M. Shin, *Methylglyoxal Induces Mitochondrial Dysfunction and Cell Death in Liver.* Toxicological Research, 2014. **30**(3): p. 193-198.
166. Lue, L.F., et al., *Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.* Am J Pathol, 1999. **155**(3): p. 853-62.

167. Martin, L., X. Latypova, and F. Terro, *Post-translational modifications of tau protein: implications for Alzheimer's disease.* Neurochem Int, 2011. **58**(4): p. 458-71.
168. Singh, S.K., et al., *Overview of Alzheimer's Disease and Some Therapeutic Approaches Targeting Abeta by Using Several Synthetic and Herbal Compounds.* Oxid Med Cell Longev, 2016. **2016**: p. 7361613.
169. Li, X.H., et al., *Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation.* Neuromolecular Med, 2012. **14**(4): p. 338-48.
170. Jackson, R.J., et al., *Human tau increases amyloid beta plaque size but not amyloid beta-mediated synapse loss in a novel mouse model of Alzheimer's disease.* Eur J Neurosci, 2016. **44**(12): p. 3056-3066.
171. Matos, M., et al., *Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: involvement of oxidative stress and mitogen-activated protein kinase cascades.* Neuroscience, 2008. **156**(4): p. 898-910.
172. Kuruva, C.S. and P.H. Reddy, *Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal.* Drug Discov Today, 2017. **22**(2): p. 223-233.
173. De Felice, F.G., et al., *Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.* Neurobiol Aging, 2008. **29**(9): p. 1334-47.
174. Ahmed, N., et al., *Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment.* Journal of Neurochemistry, 2005. **92**(2): p. 255-263.
175. Gkogkolou, P. and M. Bohm, *Advanced glycation end products: Key players in skin aging?* Dermatoendocrinol, 2012. **4**(3): p. 259-70.
176. Akter, K., et al., *Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?* British journal of clinical pharmacology, 2011. **71**(3): p. 365-376.
177. Barbagallo, M. and L.J. Dominguez, *Type 2 diabetes mellitus and Alzheimer's disease.* World journal of diabetes, 2014. **5**(6): p. 889-893.
178. Schmidt, A.M., et al., *Rage: A Novel Cellular Receptor for Advanced Glycation End Products.* Diabetes, 1996. **45**(Supplement 3): p. S77.
179. Yan, S.D., et al., *Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins.* Journal of Biological Chemistry, 1994. **269**(13): p. 9889-9897.
180. Vitek, M.P., et al., *Advanced glycation end products contribute to amyloidosis in Alzheimer disease.* Proceedings of the National Academy of Sciences, 1994. **91**(11): p. 4766-4770.
181. Jangde, N., et al., *Cysteine mediated disulfide bond formation in RAGE V domain facilitates its functionally relevant dimerization.* Biochimie, 2018. **154**: p. 55-61.
182. Wei, W., et al., *Disulfide bonds within the C2 domain of RAGE play key roles in its dimerization and biogenesis.* PLoS One, 2012. **7**(12): p. e50736.
183. Siddiqui, K.S., et al., *Role of disulfide bridges in the activity and stability of a cold-active alpha-amylase.* Journal of bacteriology, 2005. **187**(17): p. 6206-6212.
184. Takatsume, Y., S. Izawa, and Y. Inoue, *Unique regulation of glyoxalase I activity during osmotic stress response in the fission yeast Schizosaccharomyces pombe: Neither the mRNA nor the protein level of glyoxalase I increase under conditions that enhance its activity.* Archives of microbiology, 2005. **183**: p. 224-7.
185. Thornalley, P.J., *Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification--a role in pathogenesis and antiproliferative chemotherapy.* Gen Pharmacol, 1996. **27**(4): p. 565-73.

186. Westwood, M.E. and P.J. Thornalley, *Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins.* J Protein Chem, 1995. **14**(5): p. 359-72.
187. Block, A., et al., *Sex differences in protein expression in the mouse brain and their perturbations in a model of Down syndrome.* Biology of Sex Differences, 2015. **6**(1).
188. Selkoe, D.J., *Translating cell biology into therapeutic advances in Alzheimer's disease.* Nature, 1999. **399**(6738 Suppl): p. A23-31.
189. Vassar, R. and M. Citron, *Abeta-generating enzymes: recent advances in beta- and gamma-secretase research.* Neuron, 2000. **27**(3): p. 419-22.
190. Nunan, J., et al., *The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase.* Eur J Biochem, 2001. **268**(20): p. 5329-36.
191. Chang, Y., et al., *Generation of the beta-amyloid peptide and the amyloid precursor protein C-terminal fragment gamma are potentiated by FE65L1.* J Biol Chem, 2003. **278**(51): p. 51100-7.
192. O'Brien, R.J. and P.C. Wong, *Amyloid precursor protein processing and Alzheimer's disease.* Annu Rev Neurosci, 2011. **34**: p. 185-204.
193. Luth, H.J., et al., *Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains.* Cereb Cortex, 2005. **15**(2): p. 211-20.
194. Munch, G., et al., *Advanced glycation endproducts in ageing and Alzheimer's disease.* Brain Res Brain Res Rev, 1997. **23**(1-2): p. 134-43.
195. Münch, G., J. Gasic-Milenkovic, and T. Arendt. *Effect of advanced glycation endproducts on cell cycle and their relevance for Alzheimer's disease*. 2003. Vienna: Springer Vienna.
196. Ko, S.Y., et al., *The Possible Mechanism of Advanced Glycation End Products (AGEs) for Alzheimer's Disease.* PLoS One, 2015. **10**(11): p. e0143345.
197. Gandy, S. and S.T. DeKosky, *Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress.* Annu Rev Med, 2013. **64**: p. 367-83.
198. Chami, L., et al., *Nuclear factor-kappaB regulates betaAPP and beta- and gamma-secretases differently at physiological and supraphysiological Abeta concentrations.* J Biol Chem, 2012. **287**(29): p. 24573-84.
199. Schmidt, A.M., et al., *The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease.* Curr Opin Investig Drugs, 2009. **10**(7): p. 672-80.
200. Cai, Z., et al., *Role of RAGE in Alzheimer's Disease.* Cell Mol Neurobiol, 2016. **36**(4): p. 483-95.
201. Audiffret, R., *The role of the glyoxalase system and its substrate methylglyoxal in the induction of growth factor-withdrawal induced apoptosis and the regulation of the cell cycle.* 2008.
202. Barua, M., et al., *Glyoxalase I polymorphism rs2736654 causing the Ala111Glu substitution modulates enzyme activity-implications for autism.* Autism Research, 2011. **4**(4): p. 262-270.
203. Brouwers, O., et al., *Overexpression of Glyoxalase-I Reduces Hyperglycemia-induced Levels of Advanced Glycation End Products and Oxidative Stress in Diabetic Rats.* Journal of Biological Chemistry, 2010. **286**(2): p. 1374-1380.
204. Peculis, R., et al., *Identification of glyoxalase 1 polymorphisms associated with enzyme activity.* Gene, 2013. **515**(1): p. 140-143.
205. Derk, J., et al., *The Receptor for Advanced Glycation Endproducts (RAGE) and Mediation of Inflammatory Neurodegeneration.* J Alzheimers Dis Parkinsonism, 2018. **8**(1).
206. Gasic-Milenkovic, J., C. Loske, and G. Munch, *Advanced glycation endproducts cause lipid peroxidation in the human neuronal cell line SH-SY5Y.* J Alzheimers Dis, 2003. **5**(1): p. 25-30.

207. Ghasemi, R., et al., *Insulin protects against Abeta-induced spatial memory impairment, hippocampal apoptosis and MAPKs signaling disruption.* Neuropharmacology, 2014. **85**: p. 113-20.
208. Ou, Z., et al., *Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice.* Brain, Behavior, and Immunity, 2018. **69**: p. 351-363.
209. Ota, K., et al., *Metformin prevents methylglyoxal-induced apoptosis of mouse Schwann cells.* Biochemical and Biophysical Research Communications, 2007. **357**(1): p. 270-275.
210. Li, J., et al., *Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice.* Pharmacol Biochem Behav, 2012. **101**(4): p. 564-74.
211. Chen, B., et al., *Metformin Alleviated Abeta-Induced Apoptosis via the Suppression of JNK MAPK Signaling Pathway in Cultured Hippocampal Neurons.* Biomed Res Int, 2016. **2016**: p. 1421430.